Cargando…

Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model

Huntington’s disease (HD) is caused by an expansion of CAG triplets in the huntingtin gene, leading to severe neuropathological changes that result in a devasting and lethal phenotype. Neurodegeneration in HD begins in the striatum and spreads to other brain regions such as cortex and hippocampus, c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Etxeberria-Rekalde, Estibaliz, Alzola-Aldamizetxebarria, Saioa, Flunkert, Stefanie, Hable, Isabella, Daurer, Magdalena, Neddens, Joerg, Hutter-Paier, Birgit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831778/ https://www.ncbi.nlm.nih.gov/pubmed/33505246 http://dx.doi.org/10.3389/fnmol.2020.617229

Ejemplares similares

Constant Levels of Tau Phosphorylation in the Brain of htau Mice
por: Neddens, Joerg, et al.
Publicado: (2020)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Hepatic and neuronal phenotype of NPC1(−/−) mice
por: Santiago-Mujica, Estibaliz, et al.
Publicado: (2019)

Evaluation of Neuropathological Features in the SOD1-G93A Low Copy Number Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
por: Molnar-Kasza, Agnes, et al.
Publicado: (2021)

Metabolic, Phenotypic, and Neuropathological Characterization of the Tg4-42 Mouse Model for Alzheimer’s Disease
por: Hinteregger, Barbara, et al.
Publicado: (2021)

Evaluating the effect of R-Baclofen and LP-211 on autistic behavior of the BTBR and Fmr1-KO mouse models
por: Sharghi, Shirin, et al.
Publicado: (2023)

Phosphorylation of different tau sites during progression of Alzheimer’s disease
por: Neddens, Joerg, et al.
Publicado: (2018)

Transgene integration causes RARB downregulation in homozygous Tg4–42 mice
por: Hinteregger, Barbara, et al.
Publicado: (2020)

Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
por: Schiffer, Victoria, et al.
Publicado: (2020)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms
por: Scherz, Barbara, et al.
Publicado: (2018)

Decreased Plasma Aβ in Hyperlipidemic APP(SL) Transgenic Mice Is Associated with BBB Dysfunction
por: Löffler, Tina, et al.
Publicado: (2016)

Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
por: Filip, Thomas, et al.
Publicado: (2021)

Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value
por: Loeffler, Tina, et al.
Publicado: (2020)

Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches
por: Flunkert, Stefanie, et al.
Publicado: (2022)

A Comprehensive Introduction to Magnetic Resonance Imaging Relaxometry and Contrast Agents
por: Alzola-Aldamizetxebarria, Saioa, et al.
Publicado: (2022)

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
por: Rabl, R., et al.
Publicado: (2017)

Non-Selective Calcium Channel Blocker Bepridil Decreases Secondary Pathology in Mice after Photothrombotic Cortical Lesion
por: Lipsanen, Anu, et al.
Publicado: (2013)

Leukotriene Signaling as a Target in α-Synucleinopathies
por: Strempfl, Katharina, et al.
Publicado: (2022)

Stable Mutated tau441 Transfected SH-SY5Y Cells as Screening Tool for Alzheimer’s Disease Drug Candidates
por: Löffler, Tina, et al.
Publicado: (2012)

Neuroinflammation and related neuropathologies in APP(SL) mice: further value of this in vivo model of Alzheimer’s disease
por: Löffler, Tina, et al.
Publicado: (2014)

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease
por: Kutzsche, Janine, et al.
Publicado: (2017)

BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains
por: Causevic, Mirsada, et al.
Publicado: (2018)

Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease
por: Clemensson, Erik Karl Håkan, et al.
Publicado: (2019)

L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model
por: Daschil, Nina, et al.
Publicado: (2015)

Objective Acoustic Quantification of Phonatory Dysfunction in Huntington's Disease
por: Rusz, Jan, et al.
Publicado: (2013)

Correction: Objective Acoustic Quantification of Phonatory Dysfunction in Huntington's Disease
por: Rusz, Jan, et al.
Publicado: (2013)

Development of GMP‐1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease
por: Pavlov, Pavel F., et al.
Publicado: (2018)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Molecular Imaging Markers to Track Huntington’s Disease Pathology
por: Wilson, Heather, et al.
Publicado: (2017)

Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
por: Chen, Xi, et al.
Publicado: (2011)

Cardiac Dysfunction in the BACHD Mouse Model of Huntington’s Disease
por: Schroeder, Analyne M., et al.
Publicado: (2016)

Hypomorphic mutation of the mouse Huntington’s disease gene orthologue
por: Murthy, Vidya, et al.
Publicado: (2019)

Rac1 signaling in the establishment of the fucoid algal body plan
por: Hable, Whitney E.
Publicado: (2014)

Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease
por: Wijeratne, Peter A., et al.
Publicado: (2020)

Nucleolar stress controls mutant Huntington toxicity and monitors Huntington’s disease progression
por: Sönmez, Aynur, et al.
Publicado: (2021)

Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease
por: Bissonnette, Stéphanie, et al.
Publicado: (2013)

Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line
por: Czvitkovich, Stefan, et al.
Publicado: (2010)

Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays
por: Hensman Moss, Davina J., et al.
Publicado: (2017)

Gait dynamics in mouse models of Parkinson's disease and Huntington's disease
por: Amende, Ivo, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_su5rb2s3k8v173po5ceo5efubn